Niacin Lipid Profile Randomized Trial: What the Evidence Says

Quick Answer

Niacin Lipid Profile Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 narrative review, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Ezetimibe reduces low-density lipoprotein cholesterol levels and cardiovascular risk, both as monotherapy and in combination with statins. [Liu Hui-Hui (2026); evidence level 3]
• Despite robust clinical evidence and good tolerability, the adoption of ezetimibe combination therapy in real-world practice remains insufficient. [Liu Hui-Hui (2026); evidence level 3]
• Since its discovery over half a century ago, Lp(a) has attracted considerable interest due to its strong, genetically determined association with atherosclerotic cardiovascular disease (ASCVD), independent of traditional lipid risk factors. [Domański Igor (2026); evidence level 4]
• Elevated Lp(a) concentrations-particularly those above 50 mg/dL-have been strongly linked to an increased risk of myocardial infarction, ischemic stroke, peripheral artery disease, heart failure, and aortic valve stenosis. [Domański Igor (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For niacin lipid profile randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Liu Hui-Hui (2026). A Comprehensive, Updated Review of Ezetimibe: Evidence-Based Clinical Use for Atherosclerotic Cardiovascular Disease. DOI: 10.1007/s40256-026-00793-w. PMCID: PMC13260045. PMID: 42053947. License: https://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/ This article is licens.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13260045/
• Domański Igor (2026). Existing and Potential Therapeutic Strategies for Lowering Lipoprotein(a) Levels: An Update. DOI: 10.3390/jcm15062179. PMCID: PMC13027314. PMID: 41899103. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13027314/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.